Cell cycle progression is controlled by sequential activation of cyclin-dependent kinases
(CDKs), which are often deregulated in cancer. Consequently numerous pharmacological
inhibitors of CDKs have been developed with the aim of treating cancers. The article briefly
reviews CDK inhibitors and their use to treat cancers, with specific focus on the use of
biomarkers and drugs combination to improve their therapeutic efficacy.